Black Diamond Therapeutics (BDTX) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Black Diamond Therapeutics (BDTX) overview

Black Diamond Therapeutics (BDTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 70.0m and operating profit of USD 12.5m; the year-end share price was 2.43 USD and market capitalisation was USD 139m. Black Diamond Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Black Diamond Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 112mFY 2025
Share price2.43 USDFY 2025 year end
RevenueUSD 70.0mFY 2025
Operating profitUSD 12.5mFY 2025
Net earningsUSD 22.4mFY 2025
Market capitalisationUSD 139mFY 2025 year end

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing small-molecule therapies for cancers with genetically defined mutations. Its MasterKey therapies are designed to target families of oncogenic mutations, including alterations associated with treatment resistance and central nervous system disease. Its lead program, silevertinib, is an EGFR inhibitor being studied in a Phase 2 trial for patients with EGFR-mutant non-small cell lung cancer.

Generate the Black Diamond Therapeutics report

Black Diamond Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Black Diamond Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Black Diamond Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.